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Abstract 
 
Optum is a large American-based pharmacy benefit manager, healthcare consultant, 
healthcare delivery service, and business analytics corporation that has dominated the industry 
with sister-company UnitedHealthcare underneath the umbrella UnitedHealthGroup. This report 
seeks to understand through internal and external analyses how Optum’s business model and 
strategies have allowed them to gain and sustain competitive advantages in the everchanging, 
volatile environment of healthcare. Specific tools used to highlight this include Porter’s Five 
Forces, PESTEL, and SWOT analyses. Additionally, strategic recommendations are given for 
Optum’s next steps. 
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Strategic Audit 
Background 
Optum’s parent company, UnitedHealthGroup, is currently ranked 7on the Fortune 500 
list. Its two main subsidiaries, UnitedHealthcare and Optum, individually, would be within the 
Fortune 20 by their revenues, generating roughly equal amounts in 2020 (Japsen). Optum’s 
network of contacts stretches to 125 million consumers, 90% of U.S. hospitals, 80% of Fortune 
100 employers, 80% of U.S. health plan organizations, and all fifty U.S. state governments 
(Optum). Their mission statement is about making the healthcare system work better for 
everyone and to help people live healthier lives. Their core values are integrity, compassion, 
relationships, innovation, and performance – highlighting the emotional connections to its work 
and strict adherence to ethical business behavior. 
Timeline 
Optum is a fairly new company, only being officially created in April 2011 by 
UnitedHealthGroup. However, Optum’s original branches and individual components were older 
companies. First, in 1998, UnitedHealthGroup formed a health informational technology sector 
known as Ingenix and a specialized care services branch (UnitedHealthGroup). These became 
known as OptumInsight and OptumHealth, respectively. In 2005, UnitedHealthGroup bought a 
health plan, with an included pharmacy benefit manager, called PacifiCare and later incorporates 
it into Optum under the name OptumRx (BaileySouthwell). Together, OptumInsight, 
OptumHealth (recently now being called OptumCare), and OptumRx form the three main 
branches of Optum. 
After the unification under the Optum name in 2011, Optum began acquiring other 
companies from 2013 to 2018. These include MedExpress, Catamaran, and DaVita Medical 
Group. Following all these acquisitions, in 2018, Optum became the largest employer of 
physicians, having nearly 42% of them in their portfolio (BaileySouthwell).  
Business Model 
Optum is a multifaceted company that offers a wide range of services and products to a 
wide range of consumers and organizations. First, Optum owns several medical care providers 
such as private practices, surgery centers, and ambulatory/urgent care sites across the country 
(Japsen). They capitalize on these business units by offering complementary value-based medical 
benefits that intend to utilize these providers efficiently, for both financial and consumer 
wellness reasons. For example, Optum uses financial incentives to guide those under 
UnitedHealth’s insurance plans to correctly utilize their resources, such as going to a physician 
for the flu instead of going to the emergency room (Japsen). Not only does this cut costs for 
Optum but reduces cost-sharing (premiums) for the consumer as well.  
Next, Optum offers data analytics consulting to UnitedHealth for its insurance plans to by 
consulting with them on which plans and providers to improve, cut, add, or modify to connect 
the optimal number of providers and consumers. Using these analytics for competitive 
evaluations, Optum can incentivize providers to offer the best care they can, or risk losing on a 
substantial number of potential patients (and thus revenues). Also, Optum works as a pharmacy 
benefit manager, or ‘PBM’, in managing the tiering and rebates systems with major 
pharmaceutical companies as well as assisting consumers in finding the right, price-effective, 
quality drugs to use (Morse). This is especially important with developmental or experimental 
drugs that have few substitutes and are thus vulnerable to extreme price volatility and 
subjectivity. By having interests from the supply of the drug all the way to the prescription of it, 
Optum has mastered vertical integration and continues to provide a wide array of services to 
benefit all those involved in the complex healthcare system. 
Lastly, Optum does not offer insurance products and is thus not an insurer. Because of 
this label, they are free from the heavy regulations in the insurance industry that dictate how they 
allocate their money – specifically towards medical costs (Morse). This gives them the flexibility 
to adjust their expenditures given the environment around them – offering a serious competitive 
advantage in the market. 
PESTEL Analysis (Macroenvironment) 
Political 
The political climate for any affiliate to the healthcare industry is subject to mass, 
growing criticism. Much of the current healthcare system is convoluted and difficult to navigate, 
leaving room for political agendas to organize in order to rectify the system by removing the 
“middlemen” or pharmacy benefit managers (PBMs). The PBM negotiates for a discount 
(rebate) from drug manufacturers in exchange for a preferred tier in their plans. Since drug 
manufacturers want to provide the illusion of a savings for the PBM, they artificially price their 
drugs higher (Kane). However, critics of PBMs argue that this is a natural financial incentive on 
the drug manufacturers’ end, and the solution would be to remove PBMs from the equation 
altogether (Kane). 
On the more radical end, there are political calls for the transition to a single-payer or 
universal healthcare system. Proponents of this argue the current system is both inequitable and 
grossly overpriced. In fact, the U.S. spends more on health care per person ($9990) than any 
other country in the world, as of 2015 (Axene Health Partners). Some argue that this is due to the 
difference in the quality of care provided, but others claim it’s just fueled by corporate greed and 
unneeded, expensive procedures and treatments (Harrison). They also argue that healthcare 
should not be a capitalist market as it’s heavy-handed in favor of providers versus consumers 
given consumers’ reliance on needing healthcare no matter the cost (Harrison). Thus, the risk for 
political movements to strengthen and potentially find their way through the legal system 
remains high for the PBM industry. 
Economic 
Economically speaking, COVID-19 has caused serious damage to nearly every industry. 
Daily treasury rates have been in steady decline since March, the initial outbreak of COVID-19 
worldwide (U.S. Department of Treasury). Given the lockdowns and social distancing 
restrictions on everyday life, the economy has slowed to a standstill. In relation to healthcare and 
PBMs, this has been seen in a dramatic drop in the number of doctor’s visits and consequently 
healthcare claims across all regions in the U.S. (Mehrotra). Telehealth has become a viable 
substitute for many but has not mitigated for the decrease in doctor’s visits (Mehrotra). It’s 
reasonable to assume that this current recession will continue as long as the pandemic remains 
rampant, so the economic outlook for all industries is poor and unpredictable. 
Social 
Numerically based data analytics algorithms have come under criticism for their implied 
sanction of biases and systemic racial disparities. While driven by numbers and not people, some 
argue these algorithms have created outputs that seem to validate these biases and perpetuate 
them. For instance, recently a largely used algorithm used to predict health needs for different 
demographics found that black patients incurred $1800 less than their white counterparts (Paul). 
This would lead to the conclusion that black people are healthier. However, this rush to a cause-
and-effect relationship resembles racial biases as this would be the standard level of care for 
black patients. So, when they require additional care, the algorithm, and thus insurers, would flag 
it as potentially unnecessary (Paul). 
These algorithmic issues coupled with the recent racial tensions and riots in past months 
creates a sensitive and fragile social system that companies will need to tread through carefully 
and compassionately. Without proper consideration for these societal issues, healthcare 
companies could have public relations and ethical issues. 
Technological 
Big data has touched practically every industry. The collection and analysis of big data 
advise managers about the next strategic steps and potential threats. PBMs and healthcare 
insurers maintain critically important claims data to regulate pricing and determine premiums for 
various plans and demographics. Thus, data analytics play a central role in much of the 
healthcare system at large. Recently, big data analytics has seen improvements in the 
organization and accessibility of big data. Before, data would need to be collected through the 
merging of several independent databases that have different ways of recording information. 
Now, in the medical and insurance-related fields, data is grouped into a few, massive databases 
with a newfound sense of consistency (Baillie). Some have concerns regarding data privacy with 
such centralized databases but by using a “federated model”, data is accessed privately and 
securely (Baillie). This has revolutionized the speed, efficiency, and accuracy of big data 
analytics for the health industry. 
Connected to big data, machine learning and artificial intelligence have become prevalent 
as well. Typically, big data is used to monitor historical trends and then used to predict the 
future. However, with machine learning, this can become not only faster but incredibly more 
accurate. Using an artificial neural network (ANN), machines can essentially “learn” how to 
make better and better predictions over time with a constant stream of new information (Tardif). 
While this continues to be a rapidly growing practice, not many companies have explicitly 
admitted to using it. Nonetheless, it remains a hot topic in the macroenvironment and a 
foreseeably advantageous opportunity for those companies whose operations are heavily 
intertwined with big data analytics. 
Environmental 
While many healthcare-related corporations have environmental campaigns and 
initiatives, the environment plays little role in influencing their business decisions. However, if 
the perspective is to be broadened to the international market, the effect of pollution on a 
country’s population would be a worthwhile topic to further explore. 
Legal 
In mid-September, President Donald Trump addressed the crisis of rising Medicare drug 
prices in the U.S. by signing an executive order to regulate them (Keith). The order state that 
since “Americans pay more per capita for prescription drugs than residents of any other 
developed country”, the government must step in (The White House). To combat the rising 
prices, the executive order states that prescription drugs will be priced no more than the “most-
favored-nation price”, after adjustments for volume and GDP (The White House). The 
candidates for being the most-favored-nation include both American and foreign drug 
manufacturers that sell to members of the Organization for Economic Cooperation and 
Development, or OECD (The White House). Drug manufacturers were staunchly against this 
executive order, but according to White House spokesman Judd Deere, they failed to provide any 
counterproposals, so no negotiations took place (Keith). 
This has a tremendous effect on the entire chain of the healthcare industry as new, foreign 
competition has been introduced into the market. This could force pricing to become more stable 
and lower, or open the gateway for foreign drug manufacturers to cut corners to provide the 
cheapest alternatives. Either way, this changes the legal landscape tremendously and alters the 
assumptions that many healthcare insurers and PBMs currently make. 
Porter’s Five Forces Analysis (Industry-Specific) 
Although Optum operates in various industries and continues to enter new markets, this 
analysis will be restricted to the PBM industry as this is the heart of Optum’s business model. 
Industry Rivalry 
The U.S. pharmacy benefit management industry has approximately 414 businesses 
within it and operates with a market size of roughly $392 billion (IBISWorld). However, there 
are large discrepancies between the size of the individual companies as three of them dominate 
the field by providing services to insurers that cover 70% of Americans (Kane). Notably, this 
industry is seeing a growing trend of merging with healthcare insurers and those that provide 
medical benefits (Hirc). The main competition driver results from their network of relationships 
with suppliers, healthcare insurers, healthcare providers, and consumers. These relationships are 
rooted in experience and trust, thus limiting the amount of intense rivalry in this industry. 
Threat of New Entrants 
With this reliance on a complex relationship system, new entrants face tremendous 
challenges in entering the market. First, they must establish themselves as trustworthy since 
companies give them company and client data for them to analyze. Second, they must achieve 
economies of scale to provide analytics and processing at a speed comparable to internal 
analytics (IBISWorld). Third, they must have sufficient technology to compete with the most 
widely used predictive medical algorithms to offer value to any potential consumer. 
However, opportunities do exist for new entrants if they can find ways to overcome 
current problems in the PBM industry. For instance, if they can find ways to incentivize patients 
to utilize the proper drugs and methods of care, they could stand out (Hirc). Additionally, if they 
can enhance the speed of their processes or charge a vastly lower fee, they could steal clients 
away from their established relationships. Nevertheless, the threat of new entrants remains low 
given the low likelihood of a new company performing better than established ones in this 
industry. 
Threat of Substitution 
The threat of substitution is low as PBMs are considered a normal player in the 
healthcare system for processing, analytics, and benefit management needs. Technology 
currently complements PBMs’ analytics, but, if it were to require little human supervision, it 
could become a substitution. However, many deem that scenario to not be likely until far into the 
future (Baillie).  
Instead, there is a threat of industry elimination. As mentioned in the political section of 
the PESTEL analysis, there have been calls to remove any unnecessary “middlemen” in the 
healthcare process to allow for greater drug accessibility. If this movement continues to grow in 
popularity, the need for a PBM could be in danger. However, this would not imply the PBMs 
would go bankrupt, but rather be incorporated into existing healthcare insurers and stripped of 
certain privileges such as tiering and rebating with drug manufacturers.  
 
 
Bargaining Power of Suppliers 
Pharmaceutical manufacturers can either sell to PBMs or directly to the consumer. 
However, since many consumers don’t usually elect to pay for a prescription completely out-of-
pocket, most must be reached through insurers, and thus through PBMs (Kane). Therefore, the 
bargaining power of suppliers is extremely low. Pharmaceutical manufacturers need to earn back 
their heavy research and development costs while they still own the drug patent, so while they 
might have to offer a less-than-ideal price, they have to reach a large consumer base to generate 
any substantial revenue. However, this can be circumvented if they have a healthy relationship 
with a PBM who is generous with their rebate demands and tiering. Nevertheless, their 
bargaining power is weak compared to the bargaining power of the PBM in these exchanges. 
Bargaining Power of Buyers 
While PBMs might be able to exert power over their suppliers, their buyers (usually 
healthcare insurers or benefit providers) have substantial leverage. PBMs serve to process and 
pay prescription drug claims, but if this can be managed internally for cheaper, PBMs can 
become obsolete. This would require the insurer to take on the responsibilities of negotiating 
directly with the drug manufacturers themselves, but this would not be a far cry from the realm 
of possibility – especially for those of tremendous size. Therefore, the bargaining power of 
buyers is moderate as their current, already overwhelmed system is somewhat dependent on the 
PBM for efficiency, but not completely dependent. 
SWOT Analysis (Internal to Optum) 
Strengths 
One of Optum’s key strengths lies in their vertical integration tactics and implementation. 
To analyze this, we must take a step up the corporate ladder to Optum’s parent: 
UnitedHealthGroup. After UnitedHealthGroup officially “created” Optum in 2011, they took 
further steps to position Optum to control the vertical value chain. They helped to initiate the 
acquisition of companies in the surgical care (Surgical Care Affiliates), urgent care 
(MedExpress), and primary care (DaVita Medical Group) market segments to give Optum 
breadth to operate in local care delivery markets (Byers). Additionally, Optum’s data analytics 
assets set them apart from their competitors as it has given them access to the largest databases, 
which have records of upwards of 111 million lives worth of medical claims and patient survey 
data (Optum). Optum utilizes these databases in connection to publicly available demographic 
information to find key patterns and connections that can help lower their costs and generate 
efficient outcomes. 
Weaknesses 
One of Optum’s weaknesses is their lack of complete autonomy. While they serve 
various clients’ needs, they are wholly owned by UnitedHealthGroup, with an extremely strong 
tie to UnitedHealthcare as their main client. This dissuades other large health insurers to enlist 
Optum’s expertise and help as they might have concerns about the nature of Optum and 
UnitedHealthcare’s working relationships. Next, as of 2019, Optum is in litigation against their 
former executive, David Smith, for alleged leakage of trade secrets to his new employer, 
Amazon, who is trying to start a joint health venture with Berkshire Hathaway and JP Morgan 
(Coombs). Although damages might be rewarded in the case, the leakage cannot be undone and 
depending on the material of information leaked, this could lead to new imitative strategies from 
rivals in the future. Additionally, this calls into question how tight Optum’s executive board is, 
and how well they can manage their growing company and growing management team. 
 
Opportunities 
Foremost, Optum has started to begin an international expansion – having clients in 
South America and offices in the U.K., Ireland, and India. If continued, Optum could become a 
household-name in various countries, assuming they can adapt their offerings to fit into 
countries’ differing healthcare and political structures. Next, in light of COVID-19, Optum has 
considerable obligations to help prepare America for the next pandemic, whenever that may be. 
They have already begun this by coordinating with Google and Microsoft to conduct deep data 
analytics and identify key early-warning signs that were missed for COVID-19 (Landi). Lastly, 
but perhaps most importantly, Optum can expand their offerings and analysis to mental health 
via telehealth and virtual counseling. In April 2020, Optum was rumored to potentially be 
acquiring AbleTo, a virtual therapy provider that has skyrocketed since COVID-19’s social 
distancing restrictions, to integrate and build upon their presence in the mental health sector 
(Levy). If the acquisition goes through, Optum could continue to pursue related diversification 
and find new patterns and connections between patients’ physical and mental wellbeing. 
Threats 
Despite being a dominant leader in the industry, Optum does need to be careful to 
navigate the many other companies imitating their merged business structure with UnitedHealth. 
This imitation strategy might not completely level the field for these new competitors, but it does 
remove one of the chief barriers to entry. For instance, CVS and Aetna, Cigna and Express 
Scripts, and Humana and Kindred have all merged within the last few years (Byers). One of the 
major hurdles that Optum may or may not have been counting on was the antitrust laws 
regarding combining a health care provider with a healthcare insurer (as Optum is labeled as 
neither). However, as CVS and Aetna prepared to merge, a judge ruled that it was not an antitrust 
violation which has opened the floodgates up to new opportunities for any company in the 
healthcare sector looking to acquire a heavier market share (Livingston). This growing trend of 
new, imitative business models will continue to threaten Optum and force them to continually 
differentiate themselves from these competitors. 
Strategic Recommendations 
After conducting these three analyses, I have concluded upon a few key 
recommendations for Optum’s senior management in terms of their future directions. 
Brand Image 
Optum’s brand image is strong within the industry, but the industry itself has a negative 
connotation. Many Americans find the healthcare system broken, unfair, and greedy. One of the 
key antagonists in these discussions is the “unnecessary” middlemen PBMs such as Optum. 
Although they have not come under specific attack by the media, Optum should begin 
preemptively emphasizing their importance in the healthcare value chain and generate defenses 
for these critics. If Optum cannot garner public and political favor, they could quickly see 
growing regulation and oversight on their operations. Additionally, the for-profit healthcare 
system could be transformed or dismantled, so Optum needs to continue to diversify their 
holdings in order to protect against that scenario. 
Addressing the Pandemic 
As mentioned in the Opportunities section of the SWOT analysis, Optum has serious 
capabilities to analyze the failures in the handling of COVID-19 and help prepare the healthcare 
sector and general public for the next pandemic. With their core competencies rooted in data 
access and analysis, they could break away from their profit-hungry corporation image and 
transition to being a quasi-public servant. This could not only improve their brand image but 
would lead to a gain for all stakeholders in financial and community service goals alike. 
Clientele Diversification 
Optum has grown and diversified rapidly in the past few years from acquisitions, 
mergers, and vertical integration. However, they haven’t grown as much with the acquisition of 
new clients. While this would take some lobbying of UnitedHealthGroup executives, Optum 
could seek out and build new relationships with both international and domestic insurers to 
generate more business and increase their trustworthiness in being independent from 
UnitedHealthcare. Adding new clients would also enhance the expertise of Optum employees as 
they now have new databases and contacts to manage effectively. 
Stability and Sustainability 
Although Optum shows little sign of decline or distress, top management needs to be 
careful not to fall into a lull of contentment when it comes to advancing the company and 
exploring new opportunities. In the economy, in all sectors, we’ve seen companies grow to 
become dominant players yet fade away only years later. The sustainability of Optum’s 
operations is certainly feasible to assume but leadership needs to continue to be proactive in 
stressing the efficiency of current operations and quality of future innovations. Additionally, 
while acquisitions have gone smoothly so far, Optum needs to make sure to continue to integrate 
new companies into their portfolio to not lose, or water down, their central business vision or 
functional diversity. This does not exclusively apply to revenue-generating activities and 
financials, but also to the relationships with stakeholders – particularly the patients who rely on 
medical providers and knowledge that Optum helps to deploy. Managing that relationship as a 
means of environmental scanning and monitoring will help Optum find emergent trends and 
capitalize on them quickly. 
Conclusion 
Optum has revolutionized the definition of a PBM and has grown quietly to be a Fortune 
20 company with tremendous growth opportunities. Their current market position is strong, and 
they lead in business model innovations and data analysis as evidenced by the imitation 
strategies their competitors are now undertaking. Though, they must improve their brand image 
and focus their objectives on sustainability if they are to survive the eventual public spotlight that 
will be shined on them. 
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